Medigen Vaccine Biologics Corp (高端疫苗) would cooperate with the US National Institutes of Health to develop a vaccine against COVID-19, the company said yesterday, adding that it plans to begin animal testing in the second quarter of this year.
The Hsinchu-based company on Sunday signed an agreement with the US agency, which is to provide a vaccine candidate and the viral spike protein to Medigen for testing and development, spokesman Leo Lee (李思賢) told a news conference in Taipei.
Medigen Vaccine would use recombinant spike protein technology to develop the vaccine, Lee said.
Photo: Kao Shih-ching, Taipei Times
The agency last month partnered with US-based Moderna Inc to develop a vaccine utilizing messenger RNA technology.
Medigen Vaccine would inject the spike protein-based vaccine candidate into rats to observe their immunogenicity and examine whether the vaccine prototype is safe, Lee said.
While animal testing for vaccine development normally takes four to six months, the firm plans to finish the tests before the end of June to speed up the process, he added.
It then plans to apply to the Food and Drug Administration (FDA) to run a double-blind clinical test in the second half of this year, concentrating on the vaccines’ efficacy and safety, he added.
The company would not conduct human trials on infected people, but on healthy volunteers, vice chairman Charles Chen (陳燦堅) said.
“It will not be accurate to run preliminary tests on infected people. As patients’ immune systems would create antibodies, we would not know whether their recovery is attributable to their own antibodies or the vaccine’s,” Chen said.
The number of volunteers and the duration of the tests would be determined by FDA regulations, he said.
“The government might allow us to speed up the process and recruit fewer volunteers, but we expect to at least complete phase one tests or combine phase one and two tests to save time,” Chen said.
If the vaccine is proven effective, Medigen Vaccine expects to manufacture and sell it in Taiwan and neighboring countries, Chen added.
Chen, who discussed the cooperation with the US agency before the Lunar New Year holiday, said the two sides have been producing dengue vaccines since 2016.
Compared with the regular development of vaccines, the research and development costs for a vaccine against COVID-19 would be much lower due to the US agency’s resources, Medigen Vaccine financial director Jade Yang (楊郁萍) said.
Shares of Medigen Vaccine jumped 9.97 percent to close at NT$35.85 in Taipei trading yesterday.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts